BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)‐cross‐linked basophils.

[1]  G. Superti-Furga,et al.  Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth , 2016, Leukemia.

[2]  R. Valenta,et al.  IgE epitope proximity determines immune complex shape and effector cell activation capacity , 2015, The Journal of allergy and clinical immunology.

[3]  J. Bousquet,et al.  Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. , 2014, Methods.

[4]  R. Valenta,et al.  The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils , 2012, PloS one.

[5]  G. Superti-Furga,et al.  KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. , 2011, Blood.

[6]  J. Schroeder,et al.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. , 2011, International immunopharmacology.

[7]  D. MacGlashan.  Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[9]  R. Valenta,et al.  From allergen genes to allergy vaccines. , 2010, Annual review of immunology.

[10]  P. Valent,et al.  Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  D. MacGlashan,et al.  Early signal protein expression profiles in basophils: a population study , 2009, Journal of leukocyte biology.

[12]  Mi‐Sun Kim,et al.  The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells1 , 2008, The Journal of Immunology.

[13]  A. Órfão,et al.  CD203c is Overexpressed on Neoplastic Mast Cells in Systemic Mastocytosis and is Upregulated upon IgE Receptor Cross-Linking , 2008, International journal of immunopathology and pharmacology.

[14]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[15]  D. Metcalfe,et al.  Understanding the mechanisms of anaphylaxis , 2008, Current opinion in allergy and clinical immunology.

[16]  Mi‐Sun Kim,et al.  Activation and Function of the mTORC1 Pathway in Mast Cells1 , 2008, The Journal of Immunology.

[17]  G. Superti-Furga,et al.  The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. , 2008, Blood.

[18]  P. Demoly,et al.  Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives than Pitfalls , 2008, International Archives of Allergy and Immunology.

[19]  M. Greenhawt,et al.  Mastocytosis and allergy , 2007, Current opinion in allergy and clinical immunology.

[20]  G. Superti-Furga,et al.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.

[21]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[22]  T. Kawakami,et al.  Positive and Negative Regulation of Mast Cell Activation by Lyn via the FcεRI1 , 2005, The Journal of Immunology.

[23]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[24]  T. Kawakami,et al.  Early Divergence of Fcε Receptor I Signals for Receptor Up-Regulation and Internalization from Degranulation, Cytokine Production, and Survival1 , 2004, The Journal of Immunology.

[25]  Harry V. Wright,et al.  Negative Regulation of Immunoglobulin E–dependent Allergic Responses by Lyn Kinase , 2004, The Journal of experimental medicine.

[26]  P. Dráber,et al.  Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. , 2004, Current pharmaceutical design.

[27]  P. Valent,et al.  The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis , 2004, International Archives of Allergy and Immunology.

[28]  R. Valenta,et al.  Assays for measuring in vitro basophil activation induced by recombinant allergens. , 2004, Methods.

[29]  R. Siraganian.  Mast cell signal transduction from the high-affinity IgE receptor. , 2003, Current opinion in immunology.

[30]  A. Órfão,et al.  Mastocytosis: current concepts in diagnosis and treatment , 2002, Annals of Hematology.

[31]  Toshiaki Kawakami,et al.  Regulation of mast-cell and basophil function and survival by IgE , 2002, Nature Reviews Immunology.

[32]  R. Valenta,et al.  Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. , 2002, The Journal of allergy and clinical immunology.

[33]  Franco H Falcone,et al.  The human basophil: a new appreciation of its role in immune responses. , 2000, Blood.

[34]  B. Wilson,et al.  Multiple Defects in FcεRI Signaling in Syk-Deficient Nonreleaser Basophils and IL-3-Induced Recovery of Syk Expression and Secretion1 , 2000, The Journal of Immunology.

[35]  G. Marone,et al.  The clinical relevance of basophil releasability. , 1994, The Journal of allergy and clinical immunology.

[36]  O. Witte,et al.  Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking , 1994, Molecular and cellular biology.

[37]  H. Jansen,et al.  Monitoring human basophil activation via CD63 monoclonal antibody 435. , 1991, The Journal of allergy and clinical immunology.

[38]  M. Muhm,et al.  Interleukin 3 activates human blood basophils via high-affinity binding sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Ashman,et al.  Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. , 1989, Blood.

[40]  A. Olivera,et al.  New insights on mast cell activation via the high affinity receptor for IgE. , 2008, Advances in immunology.

[41]  T. Kawakami,et al.  Positive and negative regulation of mast cell activation by Lyn via the FcepsilonRI. , 2005, Journal of immunology.

[42]  M. Nadler,et al.  Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. , 2000, Advances in immunology.

[43]  J. Kinet,et al.  The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. , 1999 .

[44]  P. Valent,et al.  Cell surface structures on human basophils and mast cells: biochemical and functional characterization. , 1992, Advances in immunology.

[45]  K. Kishi,et al.  A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. , 1985, Leukemia research.